Fennec Pharmaceuticals Inc.
NASDAQ:FENCBiotechnology
-$0.12 today
- Market cap
- $470.62M
- Beta
- 1.08
- P/E (TTM)
- -36.3
- EPS (TTM)
- -$0.24
Volume 0.59M
Average 0.26M
FENC Purchases of Investments
Cash used to buy marketable securities and other investments.
Fennec Pharmaceuticals Inc.NASDAQ: FENC
Purchases of Investments · Q1 FY2026 · quarter ended Mar 2026
Purchases of investments outflow grows to $0
Q1 FY2026 purchases of investments was $0, compared with $0 a year earlier. Trailing-twelve-month purchases of investments was $0.
Context
- Purchases of investments amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
- Purchases of investments increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly purchases of investments holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.
Sources:Cash FlowText generated from reported figures; not investment advice.
Purchases of Investments history
USD · from the cash flow
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Purchases of Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Purchases of Investments vs competitors
How FENC compares with its peers on the latest reported figures
- FENC's LTM Mar 2026 purchases of investments of $0 is the 10th largest of the 11 companies compared; the peer median is $88.97M.
- Purchases of investments amounts to 0.0% of revenue for FENC, versus a peer median of 522.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $345.19M | +129.9% | +6.9% | 498.7% | |
| LTM Mar 2026 | $156.06M | -37.3% | -23.7% | 1393.0% | |
| LTM Mar 2026 | $140.56M | +49.4% | +39.7% | — | |
| LTM Mar 2026 | $113.72M | — | — | 192745.8% | |
| LTM Mar 2026 | $91.4M | +61.3% | -5.4% | 546.7% | |
| LTM Mar 2026 | $86.54M | +67.0% | +6.3% | 264.4% | |
EPRXEupraxia Pharmaceuticals Inc. | LTM Mar 2026 | $78.62M | — | — | — |
| LTM Mar 2026 | $76.65M | -17.7% | -27.0% | — | |
| LTM Mar 2026 | $4.95M | -96.0% | — | — | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding FENC) | $88.97M | +49.4% | +0.4% | 522.7% | |
Competitors are the stored peer set for FENC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (17.35M) | (23.71M) | (16.05M) | (436K) | (10.27M) |
| Depreciation & Amortization | 16K | 149K | 287K | 959K | 103K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 4.01M | 4.22M | 5.35M | 5.06M | 7.03M |
| Change in Working Capital | (138K) | (509K) | (8.17M) | (7.33M) | (15.09M) |
| Accounts Receivables | 0 | (1.55M) | (7.27M) | (7.87M) | (12.66M) |
| Inventory | 0 | (576K) | (1.58M) | 579K | (1.3M) |
| Accounts Payables | 0 | 0 | 0 | 0 | 1.42M |
| Other Working Capital | (138K) | 1.61M | 683K | (35K) | (2.55M) |
| Other Non-Cash Items | (769K) | 1.8M | 1.43M | 28.73M | 5.76M |
| Operating Cash Flow | (14.22M) | (18.06M) | (17.14M) | 26.98M | (12.47M) |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | 0 | 0 | 0 | 0 |
| Debt Repayment | 5M | 20.17M | 5M | (13M) | (19.82M) |
| Common Stock Issued | 33K | 0 | 0 | 0 | 45.01M |
| Common Stock Repurchased | 0 | (194K) | (78K) | (176K) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (55K) | 753K | 1.72M | (439K) | (2.57M) |
| Financing Cash Flow | 4.98M | 20.73M | 6.64M | (13.62M) | 22.63M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (9.24M) | 2.67M | (10.51M) | 13.37M | 10.15M |
| Free Cash Flow | (14.22M) | (18.06M) | (17.14M) | 26.98M | (12.47M) |
Fennec Pharmaceuticals Inc.
NASDAQ:FENC
Intrinsic Alpha fair value
Locked
Current Price
$13.33
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.